Drug profile · INN
sirukumab
PLIVENSIA
sirukumab (PLIVENSIA) is a interleukin-6 inhibitor.
EMA: application withdrawn Antineoplastic and immunomodulating agents (L04) L04AC
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — sirukumab
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
sirukumab (PLIVENSIA) is a interleukin-6 inhibitor.
Key facts
INN sirukumab
Brand PLIVENSIA
Mechanism Interleukin-6 inhibitor
Target Interleukin-6
Therapeutic class Antineoplastic and immunomodulating agents (L04)
ATC code L04AC
Mechanism of action
Interleukin-6 inhibitor
Primary target: Interleukin-6
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | application withdrawn | — |
Related & competitor drugs
Frequently asked questions
What is sirukumab?
sirukumab (PLIVENSIA) is a interleukin-6 inhibitor.
What is the brand name for sirukumab?
PLIVENSIA is a marketed brand name for sirukumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.